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PHARMACEUTICAL PRICING BASED ON EARLY BENEFIT ASSESSMENTS
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OBJECTIVES: After decades of free pharmaceutical pricing, Germany introduced
binding rebate negotiations between manufacturers and Statutory Health Insur-
ance funds in 2011. Negotiations are based on early benefit assessments by the
Federal Joint Committee.We aim to analyzewhether early benefit assessments can
be a basis for value-based pricing. We analyze four approaches to systematically
compute prices instead of negotiating.METHODS: A drug’s additional benefit over
a specific comparator is assessed separately for each indication (including number
of patients). Benefit is rated as: less, unproven, unquantified, small, significant, or
substantial. We analyze four models for quantifying the discrete benefit levels and
weighting of each indication. To illustrate the effects, we use data fromTicagrelor’s
early benefit assessment. RESULTS:Application of themodels to Ticagrelor results
in prices from 141 € to 579 €. All prices are adjusted to match the dose required per
patient per year. For all models, the most important factor is the comparator (as
determined by the Federal Joint Committee). Assuming Prasugrel as the compara-
tor for all indications (instead of Clopidogrel and Aspirin), the results range from
953 € to 3004 €. As the case of Ticagrelor shows, an early benefit assessment might
not recognize any additional benefit for some indications. Therefore, the impact of
the benefit levels less, unproven, and unquantified on the computation of the price
is important. CONCLUSIONS: Early benefit assessments deliver sufficient informa-
tion for systematic pharmaceutical pricing. The results of all models applied are
plausible, assuming Clopidogrel’s price of 139 € and Ticagrelor’s undiscounted
price of 1092 € as boundaries. Pricing results, however, are dependent on the prices
of the comparators. As the comparators have not been subject to early benefit
assessments, pricing remains arbitrary with regard to the drug’s value.
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OBJECTIVES:Meaningful involvement of patients in the research process is central
to patient-centered outcomes research (PCOR). However, there is currently no
agreement on what constitutes meaningful patient involvement. Objective and
transparent criteria that can be used to measure quality and effectiveness are
needed. Building onwork done in the UK, CMTP conducted a two-phase pilot study
with patients, researchers and research funders. Our objective was to identify a set
of principles formeaningful patient involvement in research to be used as the basis
for future consensus development. METHODS: During the first phase, leading pa-
tient research advocates (n12) were convened to provide input on 13 principles
through an online survey and at an in-person meeting. During the second phase,
semi-structured phone interviews (45-60 minutes) were conducted with research-
ers (n3) and research funders (n4) to better understand the barriers to and
enablers of patient involvement in research. RESULTS: Ten of 12 panelists com-
pleted the online survey, rating the principles on importance and clarity of word-
ing. All principles were rated as important, but 9 of 13 were rated as lacking clarity.
Discussion at the in-person meeting focused on improving clarity. Panelists also
stressed the importance of including researchers and research funders in develop-
ing the principles, to increase acceptance and ensure generalizability. In the sec-
ond phase, researchers and research funders identified barriers to patient involve-
ment in research, including the risk of tokenism; importance of incentives; need for
patient research advocacy education and training; and the constraint of limited
budgets and time, especially during proposal development. In both phases, pa-
tients, researchers, and research funders supported development of practical in-
dicators to go along with each principle. CONCLUSIONS: Pilot work confirmed the
need for comprehensive, feasible, and legitimate principles and indicators, which
will require consensus development among patients, researchers and research
funders.
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OBJECTIVES: In 2011, the Canadian Consumer Advocare Network conducted two
workshops to prepare patient representatives for making submissions to drug re-
view committees. A simulated drug reviewprocess allowed investigation of several
issues: perceived added value of patient submissions to the review process, poten-
tial influence of the type of drug and disease on funding recommendations, and
impact of group discussion methods on the committee deliberation process and
outcomes.METHODS: About 50% of the 90 participants in the Toronto session and
65% of the 75 in Vancouver were patient representatives. Participants were divided
into small groups (patients and non-patients separately) to simulate committees
making recommendations on drug funding. Each group reviewed information on
three of four drugs, which differed in prevalence and severity of the particular
disease, incremental benefit of the drug, and cost utility. The “committees” first
evaluated the information provided and then re-evaluated it, this time including
the patient submission. Each group used three of four “group discussion” methods
(open discussion, nominal group technique, deliberative dialogue, and multiple
attribute rating technique) to reach consensus on funding recommendations, with
the restriction that only two of the three drugs could be approved. RESULTS:Quan-
titative and qualitative responses were analyzed. All participants felt that patient
submissions added significantly to understanding the value of the drugs to pa-
tients. Themost important factor was impact on disease, its severity, the availabil-
ity of other treatment options, and risks/benefits. The multiple attribute rating
technique was the most preferred and had the most influence on achieving group
consensus. Finally, groups comprised of patient representatives behaved very sim-
ilarly to groups of non-patient representatives CONCLUSIONS: This pilot study has
shown that it is possible to achieve consensus on drug submissions, and that the
decisions were very similar, whether the group was comprised solely of patient
representatives or solely of non-patient representatives.
PHP3
VALUE-BASED DESIGN AND PRESCRIBING PATTERNS
Gibson TB1, Mahoney J2, Lucas K2, Heithoff K3, Gatwood J4
1Thomson Reuters, Ann Arbor, MI, USA, 2Florida Health Care Coalition, Orlando, FL, USA,
3Merck & Co, Inc., Whitehouse Station, NJ, USA, 4University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: A value-based pharmacy access program lowering brand name pa-
tient cost-sharing was implemented by a large manufacturer. Whether this cost-
sharing decrease also affected utilization of genericmedications and insulin is also
important for the design of future programs. The aimof this study is tomeasure the
effects of the program on utilization patterns of insulin and to determine whether
generic antidiabetic medications appear to be a complement or substitute.
METHODS: A total of 1876 adult enrollees received the value-based benefit along
with a diabetes diseasemanagement program. Enrolleeswerematched one-to-one
using propensity score matching to a comparison group of enrollees in the same
firm with disease management and without the value-based benefit. A cross-sec-
tion, time series analysis was conducted with enrollees as the cross-sectional unit
and calendar quarters from 2005 through 2008 the unit of time. We measured the
medication possession ratio and user rates for each of the medication classes and
estimatedmultivariatemodels controlling for covariates. RESULTS: The estimated
effects of the value-based program on user rates for brand name oral medications
were 2.7, 4.5, and 6.2 percentage points higher (than without the value-based pro-
gram) in the first, second, and third years of program implementation, respectively
(all p0.01). For generic medications, the effects on user rates rose in a comple-
mentary fashion andwere 4.2, 4.7 and 5.3 percentage points higher in years 1, 2 and
3, respectively (all p0.01). For insulin, the effects on user rateswere no different in
the first year, but were higher in the second and third years (both p0.01), suggest-
ing treatment augmentation with insulin occurred at a greater rate. Similar trends
were found for the medication possession ratio. CONCLUSIONS: These results
suggest that lowered cost-sharing may improve the appropriate prescribing of di-
abetesmedications, allowing for treatment decisions that aremore patient-centric
and less cost-dependent.
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OBJECTIVES: Patient’s low health literacy (LHL) continues to be a vital obstacle to
health care delivery and quality outcomes. The impact of LHL on national health
care utilization remains mostly unaddressed without knowing national health lit-
eracy level (HLL). Therefore the study aims to evaluate the impact of LHL on health
care utilization.METHODS: Study used Medical Expenditure Panel Survey (MEPS),
a nationally representative panel survey data from 2005-2008. Health literacy
scores (HLS) were estimated based on a proven predictive model using demo-
graphic and socioeconomic variables and rated according to National Assessment
of Adult Literacy (NAAL). HLL ranged from 0–500 categorized as below basic
(HLL226) to proficient HLL (HLL226). Health care utilization variables (office vis-
its, emergency room visits, and expenditures) were analyzed separately in evalu-
ating their relationship to HLL. Visits were modeled using a weighted negative
binomial regression, while expenditures were modeled using linear regression.
National estimates on individualswere estimated usingweights provided byMEPS.
Weighted multivariate logistic model was used to determine factors affecting HLL.
RESULTS:Total 503,374,648weighted individuals (mean age,48.7;SE0.186),major-
ity were from south region (36.8%), females (56.6%), Caucasian (83%), and married
(56.8%). Estimated national mean of HLS was 233.5 (SE0.34). Individuals with
below basic HLL (226) significantly(pvalue0.0001) increasing office-based visits
	0.60 (SE0.018), physician office visits 	0.77 (SE0.018), ER visits 	0.048
(SE0.001), office-based total expenditures 	$134 (SE4.0), and total prescription
expenditures 	$510 (SE9.5) compared to proficient HLL (226) group. National
extrapolated value for RxMeds shows that the extra cost of having LHL averages
$85,573,690,160/year. Logisticmodel reported individuals with higher incomewere
19 times more likely to report above basic HLL as compared to poor/near-poor
(OR18.997;CI:16.29–22.15). CONCLUSIONS: Study identifies that HLL affects
health care utilization. Consumers with proficient HLL incur fewer visits (office-
based, physician, and ER) and spend less onRxMeds.Warranting the opportunity to
save billions of national health care costs by increasing HLL.
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